Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombin generation and thrombosis risk in women using hormonal contraceptives
2026-527084-15-00Phase 4Authorised
- Sponsor
- University of Debrecen
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of avatrombopag, desogestrel, ethinyl estradiol, drospirenone, estradiol and 3 more in venous thromboembolism (VTE) (2 arms), sponsored by University of Debrecen. Primary endpoint: Normalized activated protein C sensitivity ratio. Planned start Oct 2026; status: authorised.
02
Drugs
avatrombopagdesogestrelethinyl estradioldrospirenoneestradiol
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2026-527084-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527084-15-00.